Clinical Trial: Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06931613) titled 'Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment' on April 09.

Brief Summary: Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.

Study Start Date: June 01, 2022

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Hodgkin Lymphoma Children Nivolumab Autologous Haemopo...